Muraglitazar

Muraglitazar is a dual agonist of peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma (EC50s = 0.32 and 0.11 µM, respectively). It is selective for PPARalpha/gamma over other nuclear receptors, including PPARdelta, RXRalpha, RARs, estrogen receptor alpha (ERalpha), ERbeta, androgen receptor (AR), and progesterone receptor (PR). Muraglitazar (50 µM) reduces the size of lipid droplets in oleic acid-treated HepaRG human hepatocytes. It reduces plasma levels of glucose, triglycerides, free fatty acids, and insulin by 54, 33, 62, and 48%, respectively, in db/db mice when administered at a dose of 10 mg/kg per day. Muraglitazar (10 mg/kg per day) reduces plasma levels of glucose, triglycerides, and cholesterol in diet-induced obese mice. Muraglitazar also inhibits LPS-induced increases in nitric oxide (NO) production and IL-6, TNF-alpha, and inducible nitric oxide synthase (iNOS) protein levels in J774 murine macrophages in a concentration-dependent manner. It inhibits carrageenan-induced paw edema in mice when administered at doses ranging from 12.5 to 50 mg/kg.Formal Name: N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-glycine. CAS Number: 331741-94-7. Synonyms: BMS-298585. Molecular Formula: C29H28N2O7. Formula Weight: 516.5. Purity: >90%. Formulation: (Request formulation change), A crystalline powder. Solubility: Chloroform: Slightly Soluble, DMSO: Soluble, Methanol: Slightly Soluble. SMILES: O=C(OC1=CC=C(OC)C=C1)N(CC(O)=O)CC2=CC=C(C=C2)OCCC3=C(C)OC(C4=CC=CC=C4)=N3. InChi Code: InChI=1S/C29H28N2O7/c1-20-26(30-28(37-20)22-6-4-3-5-7-22)16-17-36-24-10-8-21(9-11-24)18-31(19-27(32)33)29(34)38-25-14-12-23(35-2)13-15-25/h3-15H,16-19H2,1-2H3,(H,32,33). InChi Key: IRLWJILLXJGJTD-UHFFFAOYSA-N.